Other

Novo Nordisk joins coalition to improve the health of patients of African descent

The coalition also includes pharmaceutical companies Roche, Astrazeneca and Regeneron, each earmarking DKK 142 million for initiatives three years in the making.
Together with Roche, Astrazeneca, and Regeneron, Novo Nordisk is now joining forces with the newly established Diaspora Health Genomics Institute (DHGI) and Meharry Medical College to build a database of genome sequences from approximately 500,000 people of African descent. | Photo: Together for Change
Together with Roche, Astrazeneca, and Regeneron, Novo Nordisk is now joining forces with the newly established Diaspora Health Genomics Institute (DHGI) and Meharry Medical College to build a database of genome sequences from approximately 500,000 people of African descent. | Photo: Together for Change
by ALBERT RØNNING-ANDERSSON

It should be easier to make medicines for patients with African heritage, according to a coalition backed by some of the biggest pharmaceutical companies.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
    • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading

    Jobs